— AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) reported a net loss of $23.62 million or $0.70 per share for the third quarter of 2019, vs. $0.66 per share loss expected
— Revenues dropped to $84.13 million from $122.24 million last year, vs. $88.27 million expected
— Lowered full-year 2019 revenue guidance to $320-$330 million from the earlier outlook of $325-$355 million
— Expects full-year operating loss of $278-$268 million, up from $276 million loss estimated earlier
— Expects adjusted EBITDA loss in the range of $75 million to $65 million for 2019, which is down from the previous forecast of $85-$75 million
Jerash Holdings (US), Inc. (NASDAQ: JRSH) reported significantly improved financial results for the fiscal 2026…
Shares of Prospect Capital Corporation (PSEC) traded mixed to slightly positive in early trading on…
Waters Corporation (WAT) shares dropped 14.49% to $326.04 in early trading on Tuesday after the…
Universal Corp. (UVV) shares fell 10.72% to $51.62 in Tuesday trading after the global agriproducts…
Upwork Inc (UPWK) shares fell 4.76% to $17.89 in early trading on Tuesday after the…
Amkor (NASDAQ: AMKR) posted net sales of $1888 million. Amkor Q4 2025 earnings showed robust…